Sentences with phrase «leukemia stem»

Researchers found that the combination had an enhanced effect on leukemia stem cells, further shifting them from self - renewal back toward maturity and cell death.

This leads to the formation of so - called leukemia stem cells.

«Test predicts response to treatment for complication of leukemia stem cell treatment.»

Today's findings augment recent research also published in Nature (Dec. 7, 2016) detailing the team's development of a «stemness biomarker» — a 17 - gene signature derived from leukemia stem cells that can predict at diagnosis which AML patients will respond to standard treatment.

«By being able to distinguish benign from malignant aging based on distinctive RNA splicing patterns, we can develop therapeutic strategies that selectively target leukemia stem cells while sparing normal hematopoietic stem cells,» she said.

«How do harmful chronic myelogenous leukemia stem cells obtain their nutrients?.»

Ultimately, this activity increases cellular regeneration, or self - renewal, turning white blood cell precursors into leukemia stem cells.

Contrary to previous laboratory findings, a new study has shown for the first time the effect of stem cell burden on treatment outcome, discovering that tyrosine kinase inhibitors, including imatinib and dasatinib, can rapidly eradicate most chronic myeloid leukemia stem cells.

University researchers hope to improve the odds of surviving acute myeloid leukemia by loading a promising compound into nanoparticles that will target the inner recesses of bone marrow where leukemia stem cells lurk.

«For the first time, we have married together knowledge of stem cell biology and genetics — areas that historically have often been operating as separate camps — to identify mutations stem cells carry and how they are related to one another in AML,» says Dr. Dick, who pioneered the cancer stem cell field by identifying leukemia stem cells in 1994.

Dr. Dick says: «Our new findings add to that knowledge and we hope that we will soon have a new biomarker that will tell whether a patient will respond to standard chemotherapy, and then another to track patients in remission to identify those where treatment failed and the rare leukemia stem cells are coming back.

Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy - resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.

«We're excited by the prospect that high - dose vitamin C might become a safe treatment for blood diseases caused by TET2 - deficient leukemia stem cells, most likely in combination with other targeted therapies,» says corresponding study author Benjamin G. Neel, MD, PhD, professor in the Department of Medicine and director of the Perlmutter Cancer Center.

By inhibiting sensitivity to inflammation or inhibiting ADAR1 with a small molecule tool compound, the researchers were able to counter ADAR1's effect on leukemia stem cell self - renewal and restore let - 7.

«RNA - splicing - targeted therapies may be a potent and selective way to clear leukemia stem cells and prevent relapse.»

Current AML therapies fail to eliminate dormant leukemia stem cells responsible for disease relapse.

«Body's own gene editing system generates leukemia stem cells: Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers.»

In this study, Jamieson's team used human blast crisis chronic myeloid leukemia cells in the lab, and mice transplanted with these cells, to determine ADAR1's role in governing leukemia stem cells.

Researchers at University of California San Diego School of Medicine have now unraveled how pre-leukemic white blood cell precursors become leukemia stem cells.

Focusing on two proteins known as transcription factors, the researchers showed that genetically removing the two transcription factors, Tcf1 and Lef1, in mice is sufficient to prevent leukemia stem cells from persisting.

When the mice received no treatment or were treated with imatinib alone, the human leukemia stem cells propagated and grew to relatively large numbers.

Furthermore, niclosamide proved cytotoxic for glioblastoma and myelogeneous leukemia stem cells as well as NSCLC cells via NFκB and generation of reactive oxygen species (ROS)[37 - 39].

30 years down the road, in 1997, cancer researchers Dominique Bonnet and the above mentioned John Dick published a major report on their recently discovered leukemia stem cells in Nature Medicine, thereby starting off a whole new field in cancer research.

«The nice thing about these preclinical models is that they have well defined leukemia stem cell populations that we know reside in the bone marrow,» Frisch says.

Even after the bulk of active leukemia cells in the bloodstream are destroyed by an initial round of chemotherapy, he says, a «quiescent» subpopulation of leukemia stem cells often survives in the bone marrow.

«So it provides a nice way to test the ability of these compounds after being loaded into the nanoparticles to actually target leukemia stem cells within the bone marrow.»

Leukemia researchers at Princess Margaret Cancer Centre have developed a 17 - gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment.

Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF - kappaB pathway and generation of reactive oxygen species.

«This is the first mechanistic link between pro-cancer inflammatory signals and RNA editing - driven reprogramming of precursor cells into leukemia stem cells,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center at UC San Diego Health, director of the CIRM Alpha Stem Cell Clinic at UC San Diego School of Medicine and director of stem cell research at UC San Diego Moores Cancer Center.

One reason for this, explains Hai - Hui (Howard) Xue, MD, PhD, UI professor of microbiology and immunology, is that there are two kinds of tumor cells — bulk leukemia cells that can be killed by TKI drugs, and a subset of cells called leukemia stem cells, which are resistant to TKIs and to chemotherapy.

They will load the drug into nanoparticles that will target the inner recesses of bone marrow where leukemia stem cells lurk.

In patient - derived animal models, they found that just three doses of the compound, called 17S - FD - 895, significantly reduced the ability of leukemia stem cells to self - renew.

Yet even when this targeted therapy is successful, it is not possible to kill off all of the diseased cells — particularly the leukemia stem cells in the bone marrow.

The new biomarker is named the LSC17 score as it comes from the leukemia stem cells that drive disease and relapse.

The researchers identified the LSC17 score by sampling the leukemia stem cell properties of blood or bone marrow samples from 78 AML patients from the cancer centre combined with molecular profiling technology that measures gene expression.

Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified RNA - based biomarkers that distinguish between normal, aging hematopoietic stem cells and leukemia stem cells associated with secondary acute myeloid leukemia (sAML), a particularly problematic disease that typically afflicts older patients who have often already experienced a bout with cancer.

Leukemia stem cells promote an aggressive, therapy - resistant form of the disease called blast crisis.

Investigating how the PGE1 works to suppress the leukemia stem cells, the team found that the effect relies on a critical interaction between PGE1 and its receptor EP4.

They then tested the effect of a second drug molecule called misoprostol, which also interacts with EP4, and showed that misoprostol also has the ability to combine with TKI and significantly reduce the number of leukemia stem cells.

With that goal in mind, Xue and his team joined forces with Chen Zhao, MD, PhD, UI assistant professor of pathology, and used their understanding of CML genetics to look for small molecules or drug compounds that might be able to eradicate the leukemia stem cells.

«Prostaglandin EI inhibits leukemia stem cells: Targeting leukemia stem cells in combination with standard chemotherapy may improve treatment for chronic myeloid leukemia.»

«While it has been previously shown that ATRA's ability to degrade the leukemia - causing fusion oncogene PML - RAR causes ATRA to stop the leukemia stem cells that drive APL, the underlying mechanism has remained elusive,» says Lu.

In both cases, the mechanisms are similar: the «good» mechanism regulates healthy blood stem cells during an infection, whilst the «bad» one leads to the multiplication of leukemia stem cells.

(TORONTO, Canada — Dec. 7, 2016)-- Leukemia researchers at Princess Margaret Cancer Centre have developed a 17 - gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment.

A donor made a $ 1,009,220 contribution to the MDS - Leukemia Stem Cell Research Center at Columbia University Irving Medical Center to advance clinical and basic research in myelodysplastic syndrome and leukemia.

Studies of stable cell maintenance are being conducted in leukemia stem cells, hematopoietic stem cells, and mouse embryonic stem cells.

Using a combination of engineered enzymes and chemical methods, Fasan's lab has further modified micheliolide to develop analogs — or variants — with improved activity against both active leukemia cells and leukemia stem cells.

Researchers have found that leukemia stem cells can thrive in a patient's fatty tissue, which they can transform into a supportive hideout that makes the cancer cells more resistant to chemotherapy treatments.